The recent FDA approval of topical JAK inhibitors for children 2 years or older marks a significant advancement in pediatric ...

Incyte Biosciences Canada today announced that Health Canada has approved Opzelura® (ruxolitinib (as ruxolitinib phosphate)) ...

Roflumilast 0.05% cream, a phosphodiesterase 4 inhibitor, was approved by the FDA on October 6, having been specifically ...

The Atopic Dermatitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key ...

This approval follows the recent FDA approval of ruxolitinib cream 1.5% (Opzelura), a topical JAK inhibitor, as a treatment ...

ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere ...

Explore the latest insights on canine atopic dermatitis treatment with Joya Griffin, DVM, DACVD, and Adam Christman, DVM, MBA.

Zoryve cream gains FDA approval for treating mild to moderate atopic dermatitis in young children, offering a safe, ...

Patient BMI did not affect treatment outcomes across several efficacy measures among patients with AD who were treated with JAK inhibitors.

The FDA approved Zoryve cream 0.05% for the treatment of children aged 2 to 5 years with mild to moderate atopic dermatitis, ...

Tapinarof cream 1% is an effective and safe treatment for patients with moderate to severe AD, regardless of Fitzpatrick skin type or race.